Pharmaxis (ASX:PXS) has announced that a phase 1c trial of its novel topical drug treatment for scarring has met its primary safety objective and two secondary biomarker endpoints in patients with established scars. …
Latest Video
New Stories
-
New survey reveals most see living with COVID-19 as the 'new normal'
June 9, 2023 - - Latest News -
Industry leaders join Biointelect's new executive strategy panel
June 9, 2023 - - Latest News -
NZ patients welcome biosimilar but disappointed at failure to expand access
June 9, 2023 - - Latest News -
BMS welcomes 'One-Stop Shop' for clinical trials as an important step
June 9, 2023 - - Latest News -
The 'Week in Review' Podcast - 9 June
June 8, 2023 - - Podcast -
AVITA Medical announces US approval of RECELL for full thickness skin defects
June 8, 2023 - - Australian Biotech -
New report reveals 'crippling' impact of double dispensed quantities
June 8, 2023 - - Latest News